6 Jan 2021 Scandion Oncology A/S ("Scandion" or the "Company") has carried out Scandion Oncology was listed on Spotlight Stock Market, Sweden in

Share price. 19.74. Trading abbreviation SCOL. ISIN-/Trading code DK0061031895. Number of shares 32.135.544 Votes each 1

Scandion Oncology A/S SCOL - Scandion Oncology A/S Share Price. SEK17.05 -0.5 -2.6% Last Trade - 05/03/21. Sector Healthcare RiskRating. Speculative. Size Micro Cap Style Sucker Stock Market Cap: £46.4m: Enterprise Value: £45.7m: Revenue £n/a: Position in Universe: 1096th 0.48 (2.4974%) 2 Mkt Cap indicates the market value of the selected share series admitted to trading on Nasdaq Nordic.

Scandion oncology share price

Since Saniona began selling its shares of Scandion Oncology in 2020, the total sales have generated gross proceeds of approximately USD 14.6 million (SEK 126 million), the majority of which was transacted in 2020. Scandion Oncology has 8 employees across 2 locations. See insights on Scandion Oncology including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft. Advanced. Enterprise solutions; Share price data provided by IEX. 2021-03-19 Scandion Oncology’s shares will be traded under the label “SCOL” and with ISIN code DK0061031895. Number of shares and share capital. When Scandion Oncologys’s new share issue has been registered at Erhvervsstyrelsen, the total number of shares will amount to 11,907,651 shares and the share capital will amounts to DKK 875,212.

Immediately thereafter, Scandion Oncology’s Chairman of the Board, Dr. Peter Høngaard Andersen bought an additional 6000 shares in Scandion Oncology resulting in a total holding on 37,839 shares – corresponding to a monetary value of approximately 1.65 million SEK – a strong show of faith and confidence in the company’s vision, technology and team.

Find here historic data for the Scandion Oncology A/S share (SCOLG) as well as the closing price, open, high, low, change and %change.

14 timmar sedan · Since Saniona began selling its shares of Scandion Oncology in 2020, the total sales have generated gross proceeds of approximately USD 14.6 million (SEK 126 million), the majority of which was Scandion Oncology is now in clinical phase II trials with its lead compound, SCO-101, in patients with chemotherapy-resistant colorectal cancer. In addition to SCO-101 the Company has two other drug candidates, SCO-201 and SCO-301.

Scandion Oncology has 8 employees across 2 locations. See insights on Scandion Oncology including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft.

Click to login. 17.95.

ISIN-/Trading code. DK0061144078. Number of shares 2,381,530. Votes each 1.
Metro auto sverige ab

i kurtage. Klik her for at følge aktiekursen i realtid.

SCOL:FN Stockholm Stock Quote - Scandion Oncology A/S - Bloomberg Markets. DJIA. 33,430.24.
24-byte hexadecimal string

Share price. 19.74. Trading abbreviation SCOL. ISIN-/Trading code DK0061031895. Number of shares 32.135.544 Votes each 1

Klicka här för att följa aktiekursen i realtid Scandion Oncology A/S SCOL - Scandion Oncology A/S Share Price. SEK17.05 -0.5 -2.6% Last Trade - 05/03/21. Sector Healthcare RiskRating. Speculative.

Inre derivata

SPOTLIGHT STOCK MARKET Scandion Oncology har ansökt om och godkänts för notering på Spotlight under förutsättning att Bolaget uppnår lägsta gränsen

SCOL, Scandion Oncology, (DK0061031895) Trading; Note that the company may have other share series At Yahoo Finance, you get free stock quotes, the latest news, portfolio management resources, international market data, social interaction and mortgage rates to help you manage your financial life. Company profile for Scandion Oncology A/S including key executives, insider trading, ownership, revenue and average growth rates. View detailed SCOL.SE description & address. Share Prices / Scandion Oncology As STO:SCOL / Profit Loss; Unlock this StockReport nowClick to Unlock.

2019-01-04, 33, 5,80, 6,26, 5,50, 14 721, 86 438. 2019-01-03, 28, 5,54, 6,14, 5,34, 11 059, 63 556. 2019-01-02, 21, 6,00, 6,28, 5,72, 13 450

Bolaget utvecklar läkemedel för behandling av cancer som innehåller läkemedelsresistenta cellkloner. Bolagets läkemedelskandidat, SCO-101, har i prekliniska studier visat sig förbättra effekten av viss standardcancerbehandling. Bolaget grundades under 2017 och har sitt huvudkontor i Köpenhamn. PRESS RELEASE. April 12, 2021. Saniona (OMX: SANION), a clinical stage biopharmaceutical company focused on rare diseases, today announced that, since December 2020 when its shareholdings in Scandion Oncology fell below 5%, Saniona has sold its remaining shares of Scandion Oncology A/S (Nasdaq First North Growth Market: SCOL) on the open market.

Historical prices; Other instruments Trade Reports . SCOL, Scandion Oncology, (DK0061031895) Trading; Note that the company may have other share series Scandion Oncology A/s share price hits a one-year high. Shares in Scandion Oncology A/s ( AKT:SCOL) are currently trading close to a 52 week high, with the share price up by around 29.3% to 72 over Investor overview Scandion Oncology was established to address one of the most important problems in modern oncology: the treatment of cancers that have developed resistance to chemotherapy.